US 11,932,700 B2
Use of chimeric antigen receptor modified cells to treat cancer
Lei Xiao, Rockville, MD (US); Chengfei Pu, Shanghai (CN); Zhiyuan Cao, Shanghai (CN); He Sun, Shanghai (CN); Mao Bi, Shanghai (CN); and Zhao Wu, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY)
Filed by Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY)
Filed on Aug. 19, 2020, as Appl. No. 16/997,553.
Application 16/997,553 is a continuation of application No. 15/942,112, filed on Mar. 30, 2018, granted, now 10,793,638.
Application 15/942,112 is a continuation of application No. 15/685,670, filed on Aug. 24, 2017, granted, now 9,932,405, issued on Apr. 3, 2018.
Application 15/685,670 is a continuation in part of application No. PCT/CN2017/078740, filed on Mar. 30, 2017.
Claims priority of provisional application 62/317,261, filed on Apr. 1, 2016.
Prior Publication US 2020/0385484 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/00 (2013.01); A61K 39/39558 (2013.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/585 (2013.01); C07K 2319/33 (2013.01); C12N 7/00 (2013.01); C12N 2501/515 (2013.01)] 9 Claims
 
1. A method of stimulating a T cell-mediated immune response and treating colorectal cancer in a human patient, the method comprising:
contacting a population of cells comprising guanylate cyclase 2C (GUCY2C) comprising the amino acid sequence of SEQ ID NO: 33, in a human patient with a population of modified T cells comprising a chimeric antigen receptor (CAR),
and stimulating a T cell-mediated immune response and treating colorectal cancer in a human patient,
wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, the extracellular domain comprising the amino acid sequences SEQ ID NO: 14.